## STROBE Statement—checklist of items that should be included in reports of observational studies

| Section/item | Item No | Recommendation | Reported on Page Number/Line Number | Reported on Section/Paragraph |
|---|---|---|---|---|
| **Title and abstract** | 1 | (a) Indicate the study's design with a commonly used term in the title or the abstract | Page 1,Line 1 to 3 | Title |
| | | (b) Provide in the abstract an informative and balanced summary of what was done and what was found | Page 2-3,Line 26 to 60 | Abstract |
| **Introduction** | | | | |
| Background/ rationale | 2 | Explain the scientific background and rationale for the investigation being reported | Page 4,Line 66 to 80 | Paragraph 1 to 2 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | Page 4, Line 81 to 85 | Paragraph 3 |
| **Methods** | | | | |
| Study design | 4 | Present key elements of study design early in the paper | N/A | Reported in other section |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | Page 5, Line 89 to 90 | Paragraph 1 |
| Participants | 6 | (a) ***Cohort study***—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up<br>***Case-control study***—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls<br>***Cross-sectional study***—Give the eligibility criteria, and the sources and methods of selection of participants | Page 5, Line 91 to 104 | Paragraph 1 |
| | | (b) ***Cohort study***—For matched studies, give matching criteria and number of exposed and unexposed<br>***Case-control study***—For matched studies, give matching criteria and the number of controls per case | N/A | Not matched study |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | Page 5, Line 104 to 84 | Paragraph 1 |
| Data sources/ measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | Page 5-6, Line 105 to 111 | Paragraph 1 |
| Bias | 9 | Describe any efforts to address potential sources of bias | Page 6, Line 111 to 111 | Paragraph 1 |
| Study size | 10 | Explain how the study size was arrived at | Page 6, Line 111 to 115 | Paragraph 1 |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | Page 6, Line 121 to 121 | Paragraph 2 |

| | | | | |
|---|---|---|---|---|
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding | Page 6, Line 121 to 128 | Paragraph 2 |
| | | (b) Describe any methods used to examine subgroups and interactions | N/A | The same methods used |
| | | (c) Explain how missing data were addressed | N/A | No missing data |
| | | (d) ***Cohort study***—If applicable, explain how loss to follow-up was addressed<br>***Case-control study***—If applicable, explain how matching of cases and controls was addressed<br>***Cross-sectional study***—If applicable, describe analytical methods taking account of sampling strategy | N/A | All cases are used for comparison, no need for matching |
| | | (e) Describe any sensitivity analyses | N/A | No sensitivity analyses |
| **Results** | | | | |
| Participants | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | Yes | Figure 1 |
| | | (b) Give reasons for non-participation at each stage | Yes | Figure 1 |
| | | (c) Consider use of a flow diagram | Yes | Figure 1 |
| Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | Page 6, line 132 to 141 | Paragraph 1 |
| | | (b) Indicate number of participants with missing data for each variable of interest | Yes | In the tables using unknown |
| | | (c) ***Cohort study***—Summarise follow-up time (eg, average and total amount) | Yes median survival time was used | In table 4 |
| Outcome data | 15* | ***Cohort study***—Report numbers of outcome events or summary measures over time | Yes | In the tables and figure 2 |
| | | ***Case-control study***—Report numbers in each exposure category, or summary measures of exposure | N/A | Not Case-control study |
| | | ***Cross-sectional study***—Report numbers of outcome events or summary measures | N/A | Not Cross-sectional study |
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | Page 7-8, line 143 to 165 | Paragraph 3 to 4 |
| | | (b) Report category boundaries when continuous variables were categorized | Page 8, line 166 to 173 | Paragraph 5 |
| | | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | N/A | Not did this |
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | Page 8-9, line 174 to 187 | Paragraph 6 |
| **Discussion** | | | | |
| Key results | 18 | Summarise key results with reference to study objectives | Page 9, line 189 to 194 | Paragraph 1 |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | Page 11-12, line 244to 255 | Paragraph 8 |

| | | | | |
|---|---|---|---|---|
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | Page 9 to 11, line 195 to 243 | Paragraph 2 to 7 |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | Page 12, line 256 to 264 | Paragraph 9 |
| **Other information** | | | | |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | Page 13, line 267 to 269 | Funding |

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Article information: https://dx.doi.org/10.21037/tcr-21-1128
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.